

Persistent Complications Following Snake Envenomation: Results of a Specialized Snake Post Discharge Clinic

Erin Ryan¹; Dag Shapshak²; Katherine Griesmer²; Matthew Kelly²; Sukhshant Atti^{1,2}; Niki Ritchie¹;
Jessica Rivera^{1,2}; William Rushton^{1,2}

¹Alabama Poison Information Center, Children's of Alabama; ²University of Alabama at Birmingham

Background

Comprehensive Snakebite Program of UAB and COA	
Established	June 2021
Purpose	To provide a multidisciplinary approach to snake envenomation during and after hospitalization and to advance research in snakebite care
Specialists Involved	Medical and clinical toxicologists Wound care experts
Patient Population	Patients age \geq 5 years old throughout Alabama
Referral Process	Clinic follow up offered by poison center SPIs during hospitalization Patient contact information obtained prior to hospital discharge
Clinic Appointments	Scheduled 3-7 days after discharge Additional appointments as indicated
Interventions Provided	Compression modalities Wound care procedures (e.g. debridement) Physical therapy referrals

Table 1. Overview of the Comprehensive Snakebite Program of UAB and Children's of Alabama.

Methods

Study Design	retrospective observational study
Population	all patients evaluated in snakebite clinic between 6/1/21-12/31/22
Data Sources	clinic records, poison center charts
Statistics	Fisher's exact test, t-test
Objective	determine associations between: <ul style="list-style-type: none"> factors during acute hospitalization after envenomation complications/treatments at clinic follow up

Table 2. Design of the study.

Results

Characteristics of Clinic Patients (n=40)	
Male	20 (50%)
Age (mean, range)	34 years (5-75 years)

Table 3. Demographics of the patients seen in the clinic.




Figure 1. Species of snake involved in envenomations evaluated in clinic.

Background




Figure 2. Rates of complications (A) and interventions provided (B) in patients seen in clinic. No late coagulopathy was seen.

Results

	Lymphedema (n=29)	Lab Abnormalities During Hospitalization		
		Compression (n=21)	Interventions (n=15)	Debridement (n=4)
Fibrinogen (nadir)				
<170 (n=4)	0 (0%)	0 (0%)	1 (25%)	0 (0%)
\geq 170 (n=33)	26 (78.8%)	18 (54.5%)	13 (39.4%)	2 (6.1%)
p value	0.005	0.105	1	1
Platelets (nadir)				
<150 (n=3)	2 (66.7%)	1 (33.3%)	2 (66.7%)	0 (0%)
\geq 150 (n=37)	27 (73%)	20 (54.1%)	13 (35.1%)	4 (10.8%)
p value	1	0.596	0.545	1
WBC (peak)				
>11 (n=16)	11 (68.8%)	8 (50%)	10 (62.5%)	3 (18.8%)
\leq 11 (n=16)	11 (68.8%)	9 (56.3%)	4 (25%)	1 (6.25%)
p value	1	0.073	0.600	

Table 6. Rates of complications/interventions by lab abnormalities during initial hospitalization.

	Lymphedema (n=29)	Demographics		
		Interventions	Compression (n=21)	Physical Therapy (n=15)
Sex				
Male (n=20)	13 (65%)	7 (35%)	9 (45%)	3 (15%)
Female (n=20)	16 (80%)	14 (70%)	6 (30%)	1 (5%)
p value	0.480	0.056	0.515	0.605
Age				
\geq 18yo (n=27)	23 (85.2%)	16 (59.3%)	11 (40.7%)	3 (11.1%)
<18yo (n=13)	6 (46.2%)	5 (38.5%)	4 (30.8%)	1 (7.69%)
p value	0.020	0.314	0.730	1

Table 3. Rates of complications/interventions by patient demographics.

	Lymphedema (n=29)	Envenomation		
		Interventions	Compression (n=21)	Physical Therapy (n=15)
Species				
Agkistrodon (n=26)	21 (80.8%)	17 (65.4%)	10 (38.5%)	3 (11.5%)
Rattlesnake (n=4)	1 (25%)	0 (0%)	1 (25%)	0 (0%)
p value	0.048	0.026	1	1
Extremity				
Upper (n=17)	10 (58.8%)	17 (73.9%)	8 (47.1%)	3 (17.6%)
Lower (n=23)	19 (82.6%)	4 (23.5%)	7 (30.4%)	1 (4.35%)
p value	0.153	0.003	0.336	0.294
Bite to Digit				
Yes (n=10)	7 (70%)	3 (30%)	6 (60%)	3 (30%)
No (n=30)	22 (73.3%)	18 (60%)	9 (30%)	1 (3.3%)
p value	1	0.148	0.135	0.042

Table 4. Rates of complications/interventions by envenomation circumstances.

	Lymphedema (n=29)	Symptoms During Hospitalization		
		Interventions	Compression (n=21)	Physical Therapy (n=15)
Swelling (maximal)				
\geq 1 Major Joint (n=31)	23 (74.2%)	15 (48.4%)	14 (45.2%)	4 (12.9%)
<1 Major Joint (n=9)	6 (33.3%)	6 (33.3%)	1 (11.1%)	0 (0%)
p value	0.686	0.457	0.117	0.557
Bullae (before discharge)				
Present (n=3)	2 (66.7%)	0 (0%)	3 (100%)	2 (66.7%)
Absent (n=37)	27 (72.9%)	21 (56.8%)	12 (32.4%)	2 (5.4%)
p value	1	0.098	0.046	0.022
Systemic Symptoms				
Present (n=7)	4 (57.1%)	1 (14.3%)	3 (42.9%)	0 (0%)
Absent (n=33)	25 (75.8%)	20 (60.6%)	12 (36.4%)	4 (12.1%)
p value	0.369	0.040	1	1

Table 5. Rates of complications/interventions by symptoms during initial hospitalization.

	Lymphedema (n=29)	Therapies During Hospitalization		
		Compression (n=21)	Interventions (n=15)	Debridement (n=4)
Antivenom				
Given (n=36)	25 (69.4%)	17 (47.2%)	14 (38.9%)	4 (11.1%)
Not Given (n=4)	4 (100%)	4 (100%)	1 (25%)	0 (0%)
p value	0.560	0.108	1	1
Fab (n=32)	21 (65.6%)	13 (40.6%)	13 (40.6%)	4 (12.5%)
(Fab') ₂ (n=4)	4 (100%)	4 (100%)	1 (25%)	0 (0%)
p value	0.290	0.040	1	1
Total Vials*	9.24 v 10.6	8 v 10.8	10.3 v 9.26	6.5 v 10.1
p value	0.525	0.105	0.586	0.088
Opioids				
Given (n=33)	26 (78.8%)	18 (54.5%)	15 (45.5%)	3 (9.1%)
Not Given (n=7)	3 (42.9%)	3 (42.		